GSK plc
GSK · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $55,090,919 | $59,038,203 | $58,477,422 | $52,171,650 |
| - Cash | $3,693,000 | $3,742,813 | $3,723,000 | $5,788,919 |
| + Debt | $16,986,000 | $22,969,346 | $20,987,000 | $32,741,120 |
| Enterprise Value | $68,383,919 | $78,264,737 | $75,741,422 | $79,123,850 |
| Revenue | $31,376,000 | $30,328,000 | $29,324,000 | $24,696,000 |
| % Growth | 3.5% | 3.4% | 18.7% | – |
| Gross Profit | $22,328,000 | $21,763,000 | $19,770,000 | $16,533,000 |
| % Margin | 71.2% | 71.8% | 67.4% | 66.9% |
| EBITDA | $6,668,000 | $9,083,000 | $8,601,000 | $6,485,000 |
| % Margin | 21.3% | 29.9% | 29.3% | 26.3% |
| Net Income | $2,575,000 | $4,928,000 | $14,956,000 | $4,385,000 |
| % Margin | 8.2% | 16.2% | 51% | 17.8% |
| EPS Diluted | 1.24 | 2.4 | 2.4 | 2.7 |
| % Growth | -48.3% | 0% | -11.1% | – |
| Operating Cash Flow | $6,554,000 | $7,890,893 | $8,160,544 | $7,952,000 |
| Capital Expenditures | -$2,982,000 | -$1,633,370 | -$1,407,925 | -$2,654,000 |
| Free Cash Flow | $3,572,000 | $6,257,523 | $6,752,619 | $5,298,000 |